Use of an rxr agonist in treating drug resistant her2+ cancers

Abstract

The present specification provides combinations of active agents for the improved treatment of Her2 + cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.